IPHARMA is a contract research organization specialized in conducting clinical trials of investigational drugs in the Russian Federation and the EAEU.
-
Drug registration
IPHARMA is a member of ChemRar High-Tech Center group of companies and an accredited partner of Skolkovo Innovation Center.
Results for 2020
IPHARMA entered the TOP-3 CROs by the number of CTAs in 2020
30
16
10
1000+
3
14
New projects
CTAs obtained
Clinical trials on COVID-19
Patients with COVID-19 enrolled
Original drugs registered
Original medical devices registered
Phase III-IV clinical trial of Gam-COVID-Vac in the Republic of Belarus
New service - package insert user testing
If you would like to report an adverse drug reaction, you can do this
by phone: +7 (495) 276-11-43
e-mail: sae@ipharma.ru
or by filling out the online form on the website.
IPHARMA is now collecting information on Normacor®.
Advantages of working with IPHARMA
1. Leading positions on the market of Russian innovative drugs according to ACTO analytical report for 2013 - 2020.
2. Opportunities for drug localization, investments, and market access.
3. Full cycle of drug development: formulation, batches, QC, preclinical, clinical.
4. Medical and PV expertise with access to top scientists and KOLs.
5. Quality management systems and experienced staff.
IPHARMA contacts
5, Nobel street, Skolkovo Innovative Centre, Moscow, 121205, Russia
Tel.: +7 (495) 276-11-43
Fax: +7 (495) 276-11-47
E-mail: info@ipharma.ru
